Gregory Porreca

Title: Gregory Porreca: Innovator in Genetic Screening Technologies

Introduction

Gregory Porreca is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of genetic screening, particularly in the area of pre-implantation genetic screening (PGS). His innovative methods have the potential to enhance the efficacy and reliability of embryo selection in in vitro fertilization.

Latest Patents

Porreca holds a patent for "Methods of quality control using single-nucleotide polymorphisms in pre-implantation genetic screening." This invention provides methods for validating results of a pre-implantation genetic screen. The methods increase the efficacy of the common PGS assay FAST-SeqS by utilizing single-nucleotide polymorphisms (SNPs) generated from the assay. This approach confirms copy number calls, detects errors, identifies samples, and recognizes sources of contamination. Ultimately, these methods enhance the reliability of PGS results, making embryo selection more precise and improving outcomes of in vitro fertilization.

Career Highlights

Gregory Porreca is associated with Laboratory Corporation of America Holdings, where he applies his expertise in genetic technologies. His work focuses on advancing methodologies that improve genetic screening processes. With a patent portfolio that includes 1 patent, Porreca has established himself as a key figure in the field.

Collaborations

Porreca has collaborated with notable colleagues such as Mark Umbarger and Athurva Gore. These partnerships have contributed to the development and refinement of innovative genetic screening techniques.

Conclusion

Gregory Porreca's contributions to the field of genetic screening exemplify the impact of innovation in healthcare. His patented methods enhance the reliability of pre-implantation genetic screening, ultimately improving the success rates of in vitro fertilization.